BLRX Quote, Trading Chart, BioLineRx Ltd.
home / stock / blrx / blrx quote
$1.45 Last:
16.94% Change Percent:
$1.26 Open:
$1.45 Previous Close:
$1.45 High:
$1.2204 Low:
219,671 Volume:
05/26/2022 04:53:20 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
BLRX Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2022-05-26 | 1.26 | 1.45 | 1.45 | 1.2204 | 219,671 |
| 2022-05-25 | 1.24 | 1.24 | 1.25 | 1.185 | 150,835 |
| 2022-05-24 | 1.26 | 1.24 | 1.2636 | 1.16 | 105,974 |
| 2022-05-23 | 1.26 | 1.27 | 1.3216 | 1.25 | 69,328 |
| 2022-05-20 | 1.31 | 1.27 | 1.31 | 1.2516 | 118,609 |
| 2022-05-19 | 1.26 | 1.295 | 1.3077 | 1.25 | 95,066 |
| 2022-05-18 | 1.29 | 1.27 | 1.38 | 1.25 | 245,126 |
| 2022-05-17 | 1.18 | 1.32 | 1.34 | 1.1509 | 274,077 |
| 2022-05-16 | 1.17 | 1.16 | 1.18 | 1.15 | 106,777 |
| 2022-05-13 | 1.08 | 1.2 | 1.24 | 1.08 | 313,654 |
| 2022-05-12 | 1.05 | 1.08 | 1.11 | 1.01 | 690,797 |
| 2022-05-11 | 1.2 | 1.06 | 1.26 | 1.05 | 407,582 |
| 2022-05-10 | 1.14 | 1.21 | 1.22 | 1.14 | 275,849 |
| 2022-05-09 | 1.26 | 1.16 | 1.26 | 1.15 | 354,030 |
| 2022-05-06 | 1.25 | 1.27 | 1.28 | 1.21 | 215,003 |
| 2022-05-05 | 1.3 | 1.27 | 1.3286 | 1.24 | 195,584 |
| 2022-05-04 | 1.31 | 1.3 | 1.31 | 1.2242 | 253,300 |
| 2022-05-03 | 1.29 | 1.3 | 1.3295 | 1.29 | 82,703 |
| 2022-05-02 | 1.23 | 1.3 | 1.31 | 1.23 | 223,933 |
| 2022-04-29 | 1.26 | 1.22 | 1.33 | 1.2 | 518,824 |
BioLineRx Ltd. Company Name:
BLRX Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
-
BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire - On track to submit New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation in mid-2022, consisten...
-
BioLineRx to Report First Quarter 2022 Results on May 11, 2022 PR Newswire Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 5, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-s...
-
BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update - Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ~$360m - Successful pre-NDA meeting with FDA; NDA submission anticipated in mid-2022 - Announced highl...